| Literature DB >> 31843994 |
Fiona J McCallum1, Geoffrey W Birrell1, Marina Chavchich1, Ivor Harris1, Nicanor Obaldia2, Karin Van Breda1, Gavin D Heffernan3, David P Jacobus3, Dennis Shanks1, Michael D Edstein4.
Abstract
Nonimmune Aotus monkeys infected with Plasmodium falciparum and Plasmodium vivax were cured of their infections when treated with a single oral dose of 5 mg/kg and 10 mg/kg of the 2-aminomethylphenol, JPC-3210, respectively. Corresponding mean blood elimination half-lives of JPC-3210 were lengthy at 19.1 days and 20.5 days, respectively. This in vivo potency and lengthy half-life supports the further development of JPC-3210 as a promising, long-acting blood schizontocidal antimalarial for malaria treatment and prevention.Entities:
Keywords: Aotus monkeys; JPC-3210; Plasmodium falciparum; Plasmodium vivax; antimalarial drug discovery; in vitro drug susceptibility; pharmacokinetics
Mesh:
Substances:
Year: 2020 PMID: 31843994 PMCID: PMC7038259 DOI: 10.1128/AAC.01538-19
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191